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Abstract 1 
Background: White light (WL) is the established imaging modality for transurethral 2 
resection of bladder tumour (TURBT). Narrow band imaging (NBI) is a promising 3 
addition. 4 
Objectives: To compare 12-mo recurrence rates following TURBT using NBI versus 5 
WL guidance.   6 
Design, setting, and participants: The Clinical Research Office of the Endourology 7 
Society (CROES) conducted a prospective, randomised, single-blind, multicentre 8 
study. Patients with primary non-muscle-invasive bladder cancer (NMIBC) were 9 
randomly assigned 1:1 to TURBT guided by NBI or by WL.  10 
Intervention: TURBT for NMBIC using NBI or WL.  11 
Outcome measurements and statistical analysis: 12-mo recurrence rates were 12 
compared by chi-square tests and survival analyses.  13 
Results and limitations: Of the 965 patients enrolled in the study, 481 patients 14 
underwent WL-assisted TURBT and 484 patients received NBI-assisted TURBT. Of 15 
these, 294 and 303 patients, respectively, completed 12-mo follow-up, with 16 
recurrence rates of 27.1% and 25.4%, respectively (p = 0.585, Intention-to-treat  17 
(ITT) analysis). In patients at low risk for disease recurrence, recurrence rates at 12-18 
mo were significantly higher in the WL group compared with the NBI group: 27.3% vs 19 
5.6% (p = 0.002, ITT analysis). Although TURBT took longer on average with NBI 20 
plus WL compared with WL alone (38.1 min vs 35.0 min; p = 0.039, ITT; 39.1 vs 35.7 21 
min; p = 0.047, Per protocol (PP) analysis), lesions were significantly more often 22 
visible with NBI than with WL p =0.033). The frequency and severity of adverse 23 
events were similar in both treatment groups. Possible limitations were: lack of 24 
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uniformity of surgical resection, data on smoking status, central pathology review, 1 
and specific date regarding adjuvant intravesical instillation therapy. 2 
Conclusions: NBI and WL guidance achieved similar overall recurrence rates 12-mo 3 
after TURBT in patients with NMIBC. NBI-assisted TURBT significantly reduced the 4 
likelihood of disease recurrence in low-risk patients. 5 
 6 
Patient summary: Using a narrow band imaging technique might provide greater 7 
detection of bladder tumours and subsequent treatment, leading to reduced 8 
recurrence in low-risk patients  9 
 10 
 11 
12 
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1. Introduction 1 
The standard intervention following initial diagnosis of non-muscle invasive bladder 2 
cancer (NMIBC) is transurethral resection of bladder tumour (TURBT) with white light  3 
(WL) imaging guidance [1].  However, small bladder tumours, such as flat malignant 4 
lesions (carcinoma in situ; CIS) or small papillary tumours, can be missed [2,3].  5 
These undetected or incompletely resected tumours with diffuse borders can recur, 6 
with some becoming invasive, which emphasises the need for improved techniques 7 
to detect NMIBC. Moreover, some authors consider the majority of early recurrences 8 
to result from initial surgical failure [4].  9 
Research has focused on improved methods of detection, including narrow band 10 
imaging (NBI), a high-resolution endoscopic optical technique. Filtering white light 11 
into two bandwidths of 415 and 540 nm, which are absorbed by haemoglobin, 12 
enhances the contrast between normal urothelium and hypervascular cancer tissue. 13 
NBI enhances the submucosal capillaries and, because bladder tumours are well 14 
vascularised with densely arranged irregular vessels, the contrast between tumours 15 
and normal mucosa is improved.  16 
 17 
NBI has proved more effective than conventional WL cystoscopy [5,6]. Currently, 18 
there is limited experience with NBI in detecting bladder cancer but early results are 19 
encouraging [7−9]. The aim of the present study was to compare the efficacy and 20 
safety of TURBT using NBI or WL cystoscopy in NMIBC. We hypothesize that use of 21 
NBI at the time of TURBT will decrease recurrence rates at one year, compared to 22 
WL cystoscopy alone. 23 
 24 
2. Methods 25 
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2.1. Study design and participants 1 
The CROES NBI Study was a prospective, randomised, single-blind, multicentre trial, 2 
which was conducted at 26 specialist urological centres in 16 countries from August 3 
2010 to October 2014. The study included patients aged 18 yr or older scheduled for 4 
treatment of a primary (initially diagnosed) NMIBC; those eligible for inclusion were 5 
patients scheduled for TURBT with papillary bladder tumour(s) detected by imaging 6 
or cystoscopy or those scheduled for random biopsies and/or TURBT because of 7 
bladder lavage fluid or voided urine cytology with malignant (G3) cells. Exclusion 8 
criteria included: the presence of tumours in the upper urinary tract; muscle invasive 9 
bladder tumour; previous irradiation of the pelvis; gross haematuria (defined as heavy 10 
bladder bleeding resulting in marked amounts of blood in the urine) which might 11 
interfere with cystoscopy at the time of TURBT; participation in other clinical studies 12 
with investigational drugs either concurrently or within the last 30 d; pregnancy; and 13 
any condition associated with a risk of poor protocol compliance (for example 14 
patients with severe comorbidity interfering with thorough follow-up).  15 
 16 
Patients eligible for the study were contacted through medical staff and provided with 17 
verbal and written information. All participants were required to sign informed consent 18 
forms. The study was approved by the Institutional Review Board of each 19 
participating centre and carried out according to the guidelines of good clinical 20 
practice [1]. The trial was registered in The Netherlands Trial Register (NTR3645). All 21 
data were collected through an on-line electronic data management system 22 
(https://www.croes-dms.org). Access to this secure system was restricted to each 23 
centre investigator and CROES data managers and enabled by individual passwords.  24 
 25 
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2.2. Randomisation 1 
After enrolment, patients were randomly allocated in a 1:1 ratio to parallel control 2 
(WL) and intervention (NBI) arms. Randomisation was conducted by means of a 3 
concealed computer-generated random sequence of numbers using permuted blocks 4 
and stratified for: multiplicity (single or multiple tumours), macroscopic findings 5 
(papillary or solid/flat tumour) and age (either ≥ or < 40 yr). The process was 6 
implemented through the on-line data management system. Patients were blinded for 7 
the treatment arm they were randomised to.  8 
 9 
2.3. Procedures and follow-up 10 
In the out patients clinic, patients diagnosed as bladder tumour using WL cystoscopy  11 
were evaluated for inclusion and exclusion criteria, and preoperative data were 12 
collected, including age, gender, weight, height, ethnicity, anticoagulation therapy, 13 
co-morbidity, symptoms, urinalysis, urine culture and cytology, and upper urinary 14 
tract imaging results.  15 
 16 
In the operating room, eligible patients in both arms of the study underwent 17 
cystoscopy evaluation of the bladder and indication of all tumours using WL 18 
cystoscopy. Registration of lesions on the bladder chart included presence of lesion, 19 
type (papillary, or flat), number of lesions and location (bladder neck anterior, trigone, 20 
around ureteric orifice right, around ureteric orifice left, posterior floor, right lateral 21 
wall, cranial wall, left lateral wall, dome, anterior bladder wall and bladder neck 22 
posterior). Patients in the WL arm were then treated according to the normal hospital 23 
routines, i.e. complete resection of all papillary lesions, and biopsy and subsequent 24 
complete fulguration of all flat lesions including suspicious areas with WL. In patients 25 
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of  the NBI arm, following documentation of tumours visualized under WL and prior to 1 
resection, the bladder tumours were remapped on the bladder diagram under NBI.  2 
Then, complete resection of all papillary lesions, and biopsies and subsequent 3 
complete fulguration of all flat lesions including suspicious areas were conducted with 4 
NBI. Operative factors recorded for all patients included the date and duration of 5 
surgery, antibiotic prophylaxis, type of resection, visibility of lesion, performance of 6 
routinely random biopsies, tumour location and intraoperative complications. 7 
Postoperatively, the duration of catheterization and hospital stay, antibiotics use, 8 
pathological characteristics and complications were noted. Surveillance WL 9 
cystoscopy was planned to be done in all patients at the 3- and 12-mo follow-up 10 
visits, with histological confirmation to assess recurrence. If recurrent CIS was 11 
suspected by urine cytology, biopsy was performed to confirm CIS histologically  12 
 13 
 14 
2.4. Outcomes 15 
The primary outcome measure was recurrence rate at 1 yr. A recurrence was  16 
defined as the new occurrence of a bladder cancer at the same or different site to the 17 
index cancer. Secondary outcomes were tumour recurrence at first follow-up (3-mo 18 
post-TURBT) or presence of recurrent/residual tumour at previously resected 19 
locations (within 60 d of initial TURBT). Basically, re-resection was performed within 20 
60 d of initial TURBT with WL in both groups for patients with pT1 tumour, whose 21 
initial resected specimen did not contain sufficient muscle layer and those who were 22 
suspected of incomplete resection regardless of tumour stage. The local pathologist 23 
conducted histological assessment of both biopsied tissue and samples from 24 
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resected lesions. The study also assessed perioperative morbidity (within the first 30 1 
d of TURBT) using the Clavien-Dindo score [10]. 2 
 3 
Adverse events (AEs) were assessed and recorded for 7 d after the initial TURBT 4 
procedure or until resolution. They were also recorded at the 3- and 12-mo follow-up. 5 
AE severity was graded on a 5-point scale according to the US National Cancer 6 
Institute Common Terminology Criteria for Adverse Events v3.0 [11].  7 
 8 
2.5. Statistical analyses 9 
The expected recurrence rate in the WL-assisted TURBT group was 35% [12]. To 10 
detect a clinically relevant difference in recurrence detection rates of ≥10% at a 5% 11 
significance level and a power of 80%, the required sample size per treatment was 12 
calculated to be 329 patients (658 patients in total). To allow for a non-compliance 13 
rate of 25% and a 15% loss of patients who could be diagnosed with a pT0 or ≥pT2 14 
tumour later in the process, and assuming no crossover and no differential loss to 15 
follow-up between arms, the calculated sample size was increased proportionately 16 
resulting in a target recruitment of 946 patients. 17 
 18 
The primary efficacy analysis was performed on the intention-to-treat (ITT) 19 
population, which included those participants who were correctly randomised and 20 
were willing to participate in the study. A per protocol (PP) analysis was also 21 
performed on the study population who were correctly randomised, were willing to 22 
participate in the study and had no protocol violations. Pearson’s chi-square analysis 23 
was used for dichotomous or categorical variables. When the Pearson’s chi-square 24 
assumptions were not met, the Fisher’s exact test was used. Analysis of variance 25 
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(ANOVA) was used for continuous variables to compare characteristics and 1 
outcomes between the two groups. Survival analysis was performed using the log-2 
rank test, and shown in Kaplan Meier curves; both analyses used patient information 3 
up to the point at which censoring occurred. As all data were not available for every 4 
patient, last observation carried forward (LOCF) was also applied. The level of 5 
statistical significance was set at p < 0.05. Percentages were calculated and 6 
analyses performed on available data. A sub-analysis was conducted according to 7 
disease status, including low, intermediate and high-risk European Organisation for 8 
Research and Treatment of Cancer risk classification [12].  9 
 10 
3. Results 11 
Between August 2010 and October 2014, 981 patients at 28 centres in 14 countries 12 
(Appendix 1) were assigned to the two study groups. The trial profile is shown as a 13 
CONSORT flow diagram in Figure 1. Sixteen patients at two centres were 14 
subsequently excluded because the quality of the data could not be assured; shortly 15 
after the start of the study these centres changed to using equipment other than NBI. 16 
The ITT population thus comprised 481 patients randomised to the WL group and 17 
484 patients randomised to the NBI group. Following histopathological examination, 18 
66 patients had no available pT, or pT could not be assessed (pTx). 78 patients were 19 
excluded for muscle-invasive disease (category pT2 or higher) and absence of 20 
disease (pT0) was found in 77 patients who were then also excluded. One further 21 
patient received no intervention (surgery), leaving 365 patients in the WL group and 22 
379 patients in the NBI group available for the PP analysis. 23 
 24 
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The baseline characteristics of the patients included in this study are shown in Table 1 
1. There were no significant differences in terms of tumour location, tumour number 2 
and tumour size between the patients in the WL and the NBI groups for the ITT and 3 
PP populations. 4 
 5 
Surgery time including resection time and time for mapping out the bladder tumour 6 
was significantly longer if NBI guidance was used compared with WL (p = 0.039, 7 
ITT); this difference was also significant in the PP analysis (p = 0.047) (Table 2). A 8 
lesion was significantly more often visible in NBI compared with WL (p = 0.033, ITT). 9 
Tumour location in the dome region was significantly more frequent in the NBI group 10 
(13.9%) compared with the WL group (9.6%) for the ITT populations (p = 0.041). 11 
There were no other significant differences between the two groups in regard to 12 
tumour characteristics, operative factors or peri-operative complications (Table 2). 13 
 14 
LOCF data on the frequency of re-resection (re-TURBT) and recurrence at re-TURBT 15 
are shown in Table 3 and indicate a similar frequency in the two treatment groups. A 16 
significantly lower rate of recurrence was found in low-risk patients (pTa, Grade 1, < 17 
30 mm, and no CIS) [1] in the NBI group compared with the WL group, which was 18 
evident after 3-mo (0 vs 15.1%; p = 0.006) and 12-mo (5.6% vs 27.3%; p = 0.002) of 19 
follow-up. Similar proportions of patients completed 12-mo follow-up (n = 294 [62.6%] 20 
WL group; n = 303 [61.1%] NBI group, ITT analysis). Recurrence rates reported were 21 
27.1% (n = 109) and 25.4% (n =104) in the WL and NBI groups , respectively (p = 22 
0.585; ITT analysis).  23 
Analysis of recurrence vs time showed diverging recurrence-free survival rates for 24 
low-risk patients in the two treatment groups from 60–70 d follow-up (Fig. 2B), in 25 
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contrast to the similar rates found throughout follow-up in intermediate-risk, high-risk 1 
and all-patient groups (Fig. 2C, 2D and 2A, respectively). 2 
 3 
There were no significant differences between treatment groups in the number and 4 
severity of AEs (Appendix Table 1).  5 
 6 
4. Discussion 7 
Overall, this study found no difference in tumour recurrence between NBI-assisted 8 
TURBT and WL-assisted TURBT at 12-mo follow-up, but did find a significantly lower 9 
rate of recurrence in low-risk patients. Most of the recurrence in these patients may 10 
be due to small tumours, which are often overlooked during the TUR. We 11 
hypothesise that NBI provided greater visualisation of such overlooked lesions, 12 
therefore reducing the recurrence rate in low-risk patients. The better 3-mo 13 
recurrence-free rate in the NBI group for low risk patients may be reflective of a more 14 
complete superficial (but not deep) resection by using NBI.  In contrast, the 15 
recurrence in intermediate or high-risk patients may be caused by not only 16 
development of overlooked small tumours but also regrowth of high-grade tumour 17 
cells disseminated during TUR [13].  NBI, through more precise detection and 18 
resection of small tumours, may be able to decrease recurrence rate, but it is unlikely 19 
to influence regrowth of disseminated high-grade tumour cells. Consequently, the 20 
benefit of NBI was clear in the low-risk group but not in intermediate- or high-risk 21 
groups. 22 
 23 
Compared with published studies, the present study has a fundamental difference in 24 
its design. The inclusion of only those patients with primary tumours enables the 25 
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evaluation of a specific test in a given population. In addition, previous studies have 1 
primarily included patients with (highly) recurrent papillary tumours that are 2 
overrepresented by low risk disease. In contrast, in the present study, there was a 3 
larger patient population with intermediate- and high-risk disease (equally distributed 4 
in the WL and NBI groups). In line with this, in the present work the overall 5 
recurrence rate was significantly lower than was initially expected.  6 
 7 
The CROES Council approved all centres participating in this study and the principal 8 
investigator at each study site was a member of the Endourological Society. This 9 
high standard of uro-oncological engagement and expertise within the study is likely 10 
to have ensured efficient tumour identification and thorough resection (particularly of 11 
larger tumours) with either imaging modality. Surgeon experience and technical 12 
ability both affect the clinical outcome (including recurrence) after TURBT of new 13 
NMIBC [14], although the reliability of bladder tumour evaluation by NBI cystoscopy 14 
has been reported to be unaffected by urologists’ prior experience [15]. Furthermore, 15 
it is considered within the field that familiarity with image-enhancement modalities 16 
(such as NBI) improves a surgeon’s ability to detect small lesions with WL alone. We 17 
interpret the emergence of a difference in recurrence rate between NBI-assisted 18 
TURBT and WL-assisted TURBT only in low-risk patients as indicative of the higher 19 
efficacy of NBI in visualising smaller tumours, but we accept the possibility of 20 
observer bias e.g. double mapping favouring NBI as a limitation of this single-blind 21 
study. Furthermore, in recent years, the quality of WL imaging equipment has also 22 
improved considerably. 23 
 24 
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Assuming recurrence was caused by a tumour undetected during the first resection 1 
[13], the difference in rate of recurrence in low-risk patients between treatments 2 
evident at 3-mo post-intervention was unexpected. By including patients with primary 3 
NMIBC, we anticipated that many tumours undetected initially would still be too small 4 
to detect 3-mo after initial TURBT and that recurrences in this patient group would be 5 
detectable only after longer term follow-up.  6 
 7 
The reduction in recurrence rate in low-risk patients has obvious clinical benefits and 8 
is likely to be accompanied by favourable economic effects; lower recurrence rates 9 
with NBI compared with WL would reduce the need for further TURBTs and the 10 
frequency of surveillance [16]. Furthermore, lesions initially overlooked by WL that 11 
subsequently become visible at the 3-mo check cystoscopy would be incorrectly 12 
classed as recurrence. Management of patients with recurrence includes closer 13 
surveillance and further TURBT, resulting in increasing cost compared with 14 
identification during the preliminary examination with NBI. While the cost of the 15 
TURBT procedure is likely to be similar for NBI and WL, longer operating room use 16 
with NBI procedures in certain patients would add to resource use costs. The 17 
additional time needed is only an average of 3 min per procedure, which can be 18 
balanced against the lack of a significant difference in the frequency and the severity 19 
of grades of peri-operative complications and AEs in the two treatment groups. 20 
 21 
Several previous studies have reported improved detection of bladder tumours with 22 
NBI cystoscopy compared with standard WL cystoscopy [8,17–21]. Recent meta-23 
analyses of clinical trials in bladder cancer show that NBI provides comparable or 24 
higher diagnostic precision than WL [9,22]. Li et al calculated that an additional 17% 25 
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of patients (95% CI 10–25%) and an additional 24% of tumours (95% CI 17–31%) 1 
were detected by NBI [22].  The small number of clinical trials that have reported 2 
disease recurrence show that the use of NBI vs WL improves recurrence rates by 3 
15–32%, with time to recurrence of 29 and 13-mo, respectively [13,23–25]. The 4 
present study addresses the relative lack of prospective recurrence data for NBI. 5 
Further support for the benefits of improved visualisation of bladder tumours can be 6 
found in some studies of photodynamic diagnosis (PDD), which show recurrence-free 7 
rates at 12-mo 11–27% higher with PDD than with WL and the difference in outcome 8 
between the two techniques extended over several years [16,26]. In other studies, 9 
however, higher tumour detection rates with PDD did not translate into lower rates of 10 
NMIBC recurrence [27].  11 
 12 
In addition to earlier mentioned limitations, other possible limitations of the present 13 
study include: 1. the lack of documentation of smoking status/ongoing environmental 14 
exposures that may increase the risk of urothelial carcinoma; 2. the lack of central 15 
review pathology; 3. Lack of documentation in the use of adjuvant intravesical 16 
instillation therapy. Furthermore, we are aware of the substantial number of patients 17 
who did not receive the 3 or 12-mo follow-up cystoscopies and loss to follow-up in 18 
this study. However, this was taken into account in the sample size calculation. 19 
 20 
In summary, this large, prospective, multicentre, randomised clinical trial in patients 21 
with primary NMIBC showed that, while NBI and WL guidance achieved similar 22 
overall recurrence rates after TURBT at 12-mo follow-up, NBI-assisted TURBT 23 
significantly reduced disease recurrence in low-risk patients (pTa, Grade 1, <30 mm, 24 
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and no CIS). This finding supports the use of NBI guidance as an alternative to the 1 
current standard approach involving WL. 2 
 3 
4 
05/04/2016  
 
17 
Figure legends 1 
Fig. 1 – Study flow chart. ITT = intention-to-treat. PP = per protocol. No cystoscopy: 2 
follow-up performed without cystoscopy. Not performed: follow-up at certain moment 3 
not performed. Lost to follow-up: Patient received no further follow-up at all. Not 4 
available: no data available.   5 
Fig. 2 − Survival curves for no recurrence over a 12-mo follow-up period for the 6 
intention-to-treat population and risk subgroups following white-light- (WLI) or narrow 7 
band imaging- (NBI) assisted transurethral resection of bladder tumour. (A) all 8 
patients; (B) low-risk patients; (C) intermediate-risk patients; and (D) high-risk 9 
patients. Patients were stratified into risk groups using tumour characteristics 10 
according to European Association of Urology Guidelines [1]. CI = confidence 11 
interval.  12 
 13 
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